Elekta signs brachytherapy sales sharing agreement with Xoft8 February 2008 Oncology systems supplier Elekta has signed an agreement with California-based Xoft, Inc developer of the Axxent electronic brachytherapy system. Under the agreement, Elekta will share identified sales opportunities for Axxent in the radiation oncology market. This non-exclusive agreement allows Elekta to expand its revenue to include procedures performed outside shielded rooms by partially sharing in revenues Xoft receives from the sale of the electronic brachytherapy controller. Additionally, the companies will explore other areas of collaboration, which could include international sales and joint development agreements. Michael Klein, president and CEO of Xoft said, "This represents a true win-win situation for both companies. The Axxent system rounds out Elekta's product offering with an innovative new method of delivering partial breast irradiation in minimally shielded rooms, giving sites the ability to maximize availability of their vaults for procedures that can only be performed in shielded rooms. For Xoft, Elekta's strong radiation oncology presence and market share offers tremendous visibility and the ability to dramatically expand access to this important new treatment option. "Xoft's expansion into new treatment areas, which are pending FDA clearance, will extend the use of the electronic brachytherapy to endometrial and rectal indications and therefore allow for broader sales opportunities working with Elekta." Joseph K. Jachinowski, President and CEO of Elekta North America said, "Xoft's electronic brachytherapy system is a good example of technology improving care through the use of electronic x-ray-based therapy that can be delivered in a variety of clinical settings. This is a strong complement to Elekta's suite of oncology products designed to make cancer care easier for and more accessible to physicians and patients." |
